KeViRx is an early-stage pharmaceutical company based on intellectual property assets licensed from the University of Virginia.

Their lead compound, KVX-053, is a first-in-class small molecule inhibitor of the PTP4A3 phosphatase. KVX-053 displays potent immunomodulatory and anti-inflammatory properties necessary for repairing and restoring damaged endothelial barriers in acute lung injury.